Evaluation of the optimal dosing regimen of daptomycin based on PK-PD

Evaluation of the optimal dosing regimen of daptomycin based on PK-PD - The optimal dosing regimen of daptomycin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009743

Enrollment

Registered

2013-01-11

Start date

2012-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRSA infection

Interventions

On Days 3-7 after initial administration, venous blood samples were drawn just before the next administration and after one hour i.v. infusion.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospital patients receiving daptomycin

Exclusion criteria

Exclusion criteria: Patients receiving hemodialysis

Design outcomes

Primary

Measure	Time frame
PK-PD analysis of daptomycin is performed. The Cmax/MIC and AUC/MIC values are determined. Furthermore, we assess the relationship between daptomycin blood concentration and side effects to specify the target concentration.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026